Tumor-Infiltrating Lymphocytes (TIL) & Melanoma: A New Era of Treatment

Tumor-infiltrating lymphocyte, or TIL, therapy is a new form of cellular immunotherapy that targets cancer cells by leveraging the body’s immune system and specialized cells called T-lymphocytes. This treatment is currently approved by the U.S. Food and Drug Administration (FDA) for metastatic melanoma with additional research ongoing in other types of cancer. Dr. Manish Shah spoke with melanoma expert Dr. Barbara Ma about how this treatment works, how it differs from other therapies, the logistics of this treatment process for patients, and more. Guest: Barbara Ma, MD, MS a medical oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

You can listen to Tumor-Infiltrating Lymphocytes (TIL) & Melanoma: A New Era of Treatment online on Radio and Podcast. Open the player on this page to stream the available audio.

Tumor-Infiltrating Lymphocytes (TIL) & Melanoma: A New Era of Treatment is an episode from CancerCast by Weill Cornell Medicine.

The episode duration depends on the source podcast feed and may not always be available.

This episode was published on Sep 22, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from CancerCast when more episodes are available from the podcast feed.